Neoadjuvant Anlotinib and chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced esophageal squamous cell carcinoma: Short-term results of an open-label, randomized, phase II trial

Neoadjuvant Anlotinib and chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced esophageal squamous cell carcinoma: Short-term results of an open-label, randomized, phase II trial

BackgroundClinical benefits of neoadjuvant Anlotinib for locally advanced esophageal squamous cell carcinoma (ESCC) remains unclear. This study evaluated the efficacy and safety of neoadjuvant Anlotinib plus chemotherapy followed by minimally invasive esophagectomy (MIE) for the treatment of patient...

Full description

Bibliographic Details
Main Authors: Ying-Jian Wang, Kun-Kun Li, Xian-Feng Xie, Tao Bao, Zhi-Peng Hao, Jiang Long, Shuai Wang, Zhao-Yang Zhong, Wei Guo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
Anlotinib
chemotherapy
chemoradiotherapy
esophageal squamous cell carcinoma
minimally invasive esophagectomy
neoadjuvant therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.908841/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.908841/full

Similar Items